Johan Karlsson Wallman
1 – 10 of 39
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis
(
- Contribution to journal › Article
-
Mark
The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden in 2017
(
- Contribution to journal › Article
-
Mark
Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis : an observational nationwide study
(
- Contribution to journal › Article
-
Mark
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis : results from five Nordic biologics registries
(
- Contribution to journal › Article
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register
2022) In Scandinavian Journal of Rheumatology(
- Contribution to journal › Article
-
Mark
How good is the agreement between clinical diagnoses and classification criteria fulfilment in axial spondyloarthritis? Results from the SPARTAKUS cohort
2022) In Scandinavian Journal of Rheumatology(
- Contribution to journal › Article
-
Mark
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration
(
- Contribution to journal › Article
-
Mark
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis : Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses
(
- Contribution to journal › Article
-
Mark
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
(
- Contribution to journal › Article